GHRS (GH Research) Buildings And Improvements : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is GH Research Buildings And Improvements?

GH Research Buildings And Improvements Historical Data

The historical data trend for GH Research's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GH Research Buildings And Improvements Chart

GH Research Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Buildings And Improvements

Get a 7-Day Free Trial

GH Research Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Buildings And Improvements	Get a 7-Day Free Trial															-	-	-	-	-

GH Research Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

GH Research Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GH Research PLC (NAS:GHRS) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

1KA:Germany

Address

Dawson Street, Joshua Dawson House, Dublin 2, IRL, D02 RY95

Website

https://www.ghres.com

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.